Menu
Menu
Dive into the groundbreaking efforts being made in academia to develop trustworthy AI algorithms that address challenges related to medical imaging analysis, including delineation, in stage IV non-small cell lung cancer (NSCLC) patients, a crucial step leading towards truly personalized medicine approaches.
Discover how adding radiomic features with SOPHiA DDM™ for Radiomics, to clinical and dosimetric data enhances the prediction of acute lung toxicity in patients receiving radiotherapy for lung cancer.
We recently presented two posters at the European Congress of Pathology 2024, in Florence, Italy, in collaboration with Janssen Pharmaceutical, a Johnson & Johnson company.
ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers.
In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. The poster was recently presented at the ESMO Gynaecological Cancers Congress 2024 in Florence, Italy. Read the full spotlight:
Watch our poster spotlight interview, hosting Dr.Gardenia Vargas from Hospital del Mar in Barcelona, Spain discussing the poster presentation at ESGO 2024: “Multicenter Study To Validate And Implement SOPHiA DDM™ HRD Solution For Enhanced Molecular Diagnosis Of Ovarian Cancer.“
Discover how we collaborated with the UroCCR network to develop a machine learning model that outperformed the predictive performance of most usual kidney cancer risk scores.
Discover how a deep learning algorithm, GIInger™, leverages low-coverage sequencing data to identify homologous recombination deficiency (HRD)-induced genomic instability.
Hospices Civils de Lyon in France share their insights from 5 years of experience using NGS for the molecular diagnosis of inherited cardiac diseases.
Discover how Dr. Mohamed Z Alimohamed used Alamut™️ to develop a decision tree for the prioritization of potential RNA splice variants in cardiomyopathy genes.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.